Skip to main content
Loading market data...
Last price 37.75 USD Change: Up +0.85 Percent change: Up +2.31%

Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed

Net expense ratio
0.75%
Prospectus 29 Jun 2026
Net assets
$51.9M
As of 31 May 2026
Holdings
45
As of 31 May 2026
12-month distribution yield
1.25%
Yearly
Asset class
Equity
From holdings

Tema Heart & Health ETF (HRTS) is an exchange-traded fund listed on the Nasdaq in the United States, issued by Tema. Its category is Equity · Global (equity). Its last price was US$37.75 on 20 Oct 2026. Its net expense ratio is 0.75% a year, from its prospectus dated 29 Jun 2026. It reported net assets of US$51.92 million as of 31 May 2026. Its latest holdings report lists 45 holdings as of 31 May 2026. Over the last 12 months it paid distributions of US$0.47 a unit, a 12-month distribution yield of 1.25%, paid yearly.

General information only: nothing on TakeProfits takes into account your objectives, financial situation or needs, and it isn't personal financial advice or a recommendation to buy or sell anything. Consider whether it suits you and get advice from a licensed adviser before acting. Market data may be delayed and comes from third-party sources.

Fees

Total annual operating expenses (gross)
0.99%
Net, after fee waivers or reimbursements
0.75%
Management fee
0.99%
Prospectus date
29 Jun 2026
Filed with the SEC
29 Jun 2026

Size and reporting

Net assets
$51,915,425
Total assets
$51,947,871
Holdings as of
31 May 2026
Report made public
29 Jul 2026 (59 days after the month end)

Net assets are for the whole fund series, which for some funds (Vanguard's, for example) also includes mutual fund share classes.

Top holdings

Largest 25 of 45 positions, as of 31 May 2026. Weight is the percent of net assets the fund reported.

HRTS top holdings as of 31 May 2026
# Holding Identifier Weight Value (USD) Type Country Currency
1 Eli Lilly & Co US5324571083 11.52% $6.0M Equity (common) United States USD
2 UnitedHealth Group Inc US91324P1021 5.24% $2.7M Equity (common) United States USD
3 Novo Nordisk A/S DK0062498333 5.24% $2.7M Equity (common) Denmark DKK
4 Roche Holding AG US7711951043 4.50% $2.3M Equity (common) Switzerland USD
5 Merck & Co Inc US58933Y1055 4.27% $2.2M Equity (common) United States USD
6 AstraZeneca PLC GB0009895292 4.00% $2.1M Equity (common) United Kingdom GBP
7 Thermo Fisher Scientific Inc US8835561023 3.97% $2.1M Equity (common) United States USD
8 Johnson & Johnson US4781601046 3.59% $1.9M Equity (common) United States USD
9 Gilead Sciences Inc US3755581036 3.43% $1.8M Equity (common) United States USD
10 Novartis AG CH0012005267 3.38% $1.8M Equity (common) Switzerland CHF
11 Revolution Medicines Inc US76155X1000 3.33% $1.7M Equity (common) United States USD
12 Vertex Pharmaceuticals Inc US92532F1003 2.93% $1.5M Equity (common) United States USD
13 Danaher Corp US2358511028 2.66% $1.4M Equity (common) United States USD
14 Abbott Laboratories US0028241000 2.61% $1.4M Equity (common) United States USD
15 Bridgebio Pharma Inc US10806X1028 2.59% $1.3M Equity (common) United States USD
16 Cytokinetics Inc US23282W6057 2.52% $1.3M Equity (common) United States USD
17 AbbVie Inc US00287Y1091 2.40% $1.2M Equity (common) United States USD
18 Bristol-Myers Squibb Co US1101221083 2.09% $1.1M Equity (common) United States USD
19 Teva Pharmaceutical Industries Teva Pharmaceutical Industries Ltd US8816242098 2.06% $1.1M Equity (common) Israel USD
20 Dexcom Inc US2521311074 1.92% $996K Equity (common) United States USD
21 Amgen Inc US0311621009 1.91% $992K Equity (common) United States USD
22 Medtronic PLC IE00BTN1Y115 1.88% $975K Equity (common) Ireland USD
23 Edwards Lifesciences Corp US28176E1082 1.75% $907K Equity (common) United States USD
24 McKesson Corp US58155Q1031 1.71% $888K Equity (common) United States USD
25 Regeneron Pharmaceuticals Inc US75886F1075 1.67% $866K Equity (common) United States USD

Breakdowns

Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.

Asset type

Asset type by weight
TypeWeightBar
Equity (common) 99.16%
Short-term investment vehicles (cash funds) 0.72%

Country

Country by weight
CountryWeightBar
United States 74.86%
Switzerland 7.88%
Denmark 6.99%
United Kingdom 4.00%
Israel 2.06%
Ireland 1.88%
Japan 1.33%
Canada 0.88%

Currency exposure

Currency exposure by weight
CurrencyWeightBar
US dollar (USD) 84.94%
Danish krone (DKK) 6.23%
British pound (GBP) 4.00%
Swiss franc (CHF) 3.38%
Japanese yen (JPY) 1.33%

Sector

Sector weights for holdings matched to listed stocks
SectorWeightBar
Health Care 68.61%
Industrials 6.63%

Source: SEC Form N-PORT (opens in a new tab) Holdings as of

Distributions

Paid in the last 12 months
$0.4730
1 payment per unit
12-month yield
1.25%
Distributions only, not total return
Frequency
Yearly
From the gaps between ex-dates
Latest ex-date
10 Dec 2025

12-month yield = distributions per unit with an ex-date in the last 12 months ($0.4730) ÷ latest price ($37.75) × 100 = 1.25%. It looks back, so it is not a forecast; special distributions in the window are included.

Why a distribution yield is not the fund's return: yield vs total return

Distribution history table (2 payments)
HRTS distributions per unit by ex-date
Ex-dateAmount per unit
10 Dec 2025$0.4730
11 Dec 2024$0.4690

Filings and sources

Compare with

Largest funds in the same category:

Up to four symbols separated by commas. ASX funds end in .AX, for example IVV.AX.

How ETF overlap is measured, with a worked example

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.

Catalyst evidence

Loading…

Loading evidence…

Supporting sources

    Skip to main content

    All resources and tools

    Market ticker

    Markets

    Research

    Tools

    My investments

    Account

    Region and currency

    Colour theme